Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677. [Epub ahead of print]

PMID:
31721282
2.

GDF-15 in solid vs non-solid treatment-naïve malignancies.

Arfsten H, Cho A, Freitag C, Raderer M, Goliasch G, Bartko PE, Wurm R, Strunk G, Gisslinger H, Marosi C, Kornek G, Zielinski C, Hülsmann M, Pavo N.

Eur J Clin Invest. 2019 Nov;49(11):e13168. doi: 10.1111/eci.13168. Epub 2019 Sep 26.

PMID:
31463975
3.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM.

Haematologica. 2019 Dec;104(12):e551-e554. doi: 10.3324/haematol.2018.209965. Epub 2019 May 9. No abstract available.

4.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.

5.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C.

Br J Haematol. 2019 May;185(4):691-700. doi: 10.1111/bjh.15824. Epub 2019 Mar 28.

6.

Comments on pre-fibrotic myelofibrosis and how should it be managed.

Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A.

Br J Haematol. 2019 Jul;186(2):358-360. doi: 10.1111/bjh.15840. Epub 2019 Mar 7. No abstract available.

PMID:
30847907
7.

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.

Pavo N, Arfsten H, Cho A, Goliasch G, Bartko PE, Wurm R, Freitag C, Gisslinger H, Kornek G, Strunk G, Raderer M, Zielinski C, Hülsmann M.

Sci Rep. 2019 Feb 22;9(1):2554. doi: 10.1038/s41598-019-38867-2.

8.

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V.

Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11.

9.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Krauth MT, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Keil F, Krippl P, Melchardt T, Petzer A, Rumpold H, Sliwa T, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2019 Jan;131(1-2):47. doi: 10.1007/s00508-018-1428-7.

10.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

11.

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.

Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT.

BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0.

12.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ.

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.

13.

Recommendations for the diagnosis and treatment of patients with polycythaemia vera.

Hatalova A, Schwarz J, Gotic M, Penka M, Hrubisko M, Kusec R, Egyed M, Griesshammer M, Podolak-Dawidziak M, Hellmann A, Klymenko S, Niculescu-Mizil E, Petrides PE, Grosicki S, Sever M, Cantoni N, Thiele J, Wolf D, Gisslinger H.

Eur J Haematol. 2018 Jul 30. doi: 10.1111/ejh.13156. [Epub ahead of print]

PMID:
30058088
14.

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Krauth MT, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Keil F, Krippl P, Melchardt T, Petzer A, Rumpold H, Sliwa T, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2018 Sep;130(17-18):495-504. doi: 10.1007/s00508-018-1365-5. Epub 2018 Jul 24. Erratum in: Wien Klin Wochenschr. 2019 Jan;131(1-2):47.

15.

Austrian recommendations for the management of polycythemia vera.

Burgstaller S, Buxhofer-Ausch V, Sliwa T, Beham-Schmid C, Gastl G, Geissler K, Melchardt T, Krauth M, Krippl P, Petzer A, Rumpold H, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2018 Sep;130(17-18):535-542. doi: 10.1007/s00508-018-1359-3. Epub 2018 Jul 19. Review.

PMID:
30027395
16.

Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count.

Gremmel T, Gisslinger B, Gisslinger H, Panzer S.

Transl Res. 2018 Oct;200:35-42. doi: 10.1016/j.trsl.2018.05.009. Epub 2018 Jun 13.

PMID:
30012347
17.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768.

PMID:
29907599
18.

The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.

Jakovic L, Gotic M, Gisslinger H, Soldatovic I, Sefer D, Tirnanic M, Lekovic D, Jovanovic MP, Schalling M, Gisslinger B, Beham-Schmid C, Simonitsch-Klupp I, Thiele J.

Ann Hematol. 2018 Sep;97(9):1581-1590. doi: 10.1007/s00277-018-3344-3. Epub 2018 May 1.

PMID:
29717365
19.

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Schalling M, Krauth MT, Thiele J, Ruckser R, Gastl G, Gisslinger H.

Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13070. [Epub ahead of print]

PMID:
29603799
20.

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.

Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.

21.

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.

Schalling M, Gleiss A, Gisslinger B, Wölfler A, Buxhofer-Ausch V, Jeryczynski G, Krauth MT, Simonitsch-Klupp I, Beham-Schmid C, Thiele J, Gisslinger H.

Blood Cancer J. 2017 Dec 13;7(12):643. doi: 10.1038/s41408-017-0006-y. No abstract available.

22.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

23.

Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.

Pavo N, Raderer M, Goliasch G, Wurm R, Strunk G, Cho A, Novak JF, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider ST, Parschalk B, Scheithauer W, Pirker R, Kiesewetter B, Pacher R, Zielinski C, Hülsmann M.

Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. eCollection 2017 Oct 6.

24.

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M.

Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.

25.

Pre-PMF emerging as important subgroup of MPN.

Gisslinger H.

Blood. 2017 Jun 15;129(24):3142-3144. doi: 10.1182/blood-2017-04-777805. No abstract available.

PMID:
28620103
26.

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, Burgstaller S, Buxhofer-Ausch V, Sliwa T, Schlögl E, Geissler K, Krauth MT, Nader A, Vesely M, Simonitsch-Klupp I, Müllauer L, Beham-Schmid C, Gisslinger H.

Am J Hematol. 2017 Sep;92(9):885-891. doi: 10.1002/ajh.24788. Epub 2017 Jun 9.

27.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.

PMID:
28465517
28.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323. No abstract available.

PMID:
28248313
29.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth MT, Schiefer AI, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J.

Leukemia. 2017 Mar;31(3):774-775. doi: 10.1038/leu.2016.291. No abstract available.

PMID:
28248312
30.

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A.

Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. Epub 2017 Mar 4. No abstract available.

31.

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Krauth M, Krippl P, Lang A, Petzer A, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2017 May;129(9-10):293-302. doi: 10.1007/s00508-016-1120-8. Epub 2016 Dec 13.

PMID:
27966016
32.

Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P.

Haematologica. 2016 Dec;101(12):e492. No abstract available.

33.

Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'.

Gisslinger H, Jeryczynski G, Wölfler A, Beham-Schmid C, Thiele J.

Leukemia. 2017 Mar;31(3):768-769. doi: 10.1038/leu.2016.319. Epub 2016 Nov 29. No abstract available.

34.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum in: Leukemia. 2017 May;31(5):1252.

35.

The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.

Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. No abstract available.

36.

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Buxhofer-Ausch V, Gisslinger B, Schalling M, Gleiss A, Schiefer AI, Müllauer L, Thiele J, Kralovics R, Gisslinger H.

Br J Haematol. 2017 Oct;179(1):166-169. doi: 10.1111/bjh.14202. Epub 2016 Jul 19. No abstract available.

PMID:
27432009
37.

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A.

Blood Rev. 2016 Nov;30(6):453-459. doi: 10.1016/j.blre.2016.06.001. Epub 2016 Jun 11. Review.

PMID:
27341755
38.

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T.

J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295.

PMID:
27325857
39.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23. Erratum in: Leukemia. 2017 Mar;31(3):775.

40.

In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.

Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P.

Eur J Haematol. 2016 Dec;97(6):562-567. doi: 10.1111/ejh.12773. Epub 2016 Jun 15.

PMID:
27157043
41.

[In Process Citation].

Gisslinger H, Penka M.

Leuk Res. 2016 May;44 Suppl 1:v. doi: 10.1016/S0145-2126(16)30070-4. Epub 2016 Apr 26. No abstract available.

PMID:
27130523
42.

Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.

Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Ruckser R, Gastl G, Gisslinger H.

Eur J Haematol. 2016 Dec;97(6):511-516. doi: 10.1111/ejh.12759. Epub 2016 May 23.

PMID:
27037858
43.

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T.

Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. Review.

PMID:
26854026
44.

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans.

Kornienko AE, Dotter CP, Guenzl PM, Gisslinger H, Gisslinger B, Cleary C, Kralovics R, Pauler FM, Barlow DP.

Genome Biol. 2016 Jan 29;17:14. doi: 10.1186/s13059-016-0873-8.

45.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth MT, Schiefer AI, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J.

Leukemia. 2016 May;30(5):1126-32. doi: 10.1038/leu.2015.360. Epub 2015 Dec 29. Erratum in: Leukemia. 2017 Mar;31(3):774-775.

46.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.

47.

Erratum to: Iron metabolism and iron supplementation in cancer patients.

Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H.

Wien Klin Wochenschr. 2015 Dec;127(23-24):920-1. doi: 10.1007/s00508-015-0893-5. No abstract available.

48.

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R.

Blood. 2016 Jan 21;127(3):362-5. doi: 10.1182/blood-2015-09-668673. Epub 2015 Nov 16. No abstract available.

49.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R.

Blood. 2016 Jan 21;127(3):325-32. doi: 10.1182/blood-2015-07-661835. Epub 2015 Sep 30.

50.

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R.

Heart. 2015 Dec;101(23):1874-80. doi: 10.1136/heartjnl-2015-307848. Epub 2015 Sep 28.

PMID:
26416836

Supplemental Content

Loading ...
Support Center